A Bibliometric Analysis of the Top 100 Most-Cited Articles in Chemotherapy (1910- 2019)
Mohammad FaisalUddin1, Pulwasha Maria Iftikhar2*, Roopam Bansal3, Azadeh Khayat1, Azeem Husain Arastu1, Javidulla Khan1 and Jain Akriti4
1Department of Medicine, Deccan College of Medical Science, India
2Department of Health Sciences, St John’s University, Queens, USA
3Department of Medicine, Sagar Gian Medical College, India
4Florida hospital, Orlando, USA
Submission: October 29, 2019; Published: December 06, 2019
*Corresponding Address: Iftikhar Pulwasha Maria, Department of Health Sciences, St John’s University, Queens, New York, USA
How to cite this article:Mohammad F, Pulwasha M I, Roopam B, Azadeh K, Azeem H A, Javidulla K and Jain A, et al. A Bibliometric Analysis of the Top 100 Most-Cited Articles in Chemotherapy (1910- 2019). Canc Therapy & Oncol Int J. 2019; 15(2): 555908. DOI:10.19080/CTOIJ.2019.15.555908
Abstract
Background: Chemotherapy is the foundation for the treatment of various cancers. The advent of targeted treatment and chemotherapy has excited clinicians and scientists to perform clinical trials and studies. With limited medical care resources, bibliometric studies can help guide both researchers and research funding organizations to reallocate and increase the research activity.
Objective: To identify, characterize and review the 100 most-cited articles in the field of chemotherapy focusing on papers that modified therapeutic concepts and influenced the oncologist’s decision making.
Methods: Two independent researchers, Iftikhar PM, Uddin MF explored the databases of Scopus, Web of Science and Google Scholar with truncated search term ‘‘chemotherapy” to extract articles between 1910 and Aug 2019. After an extensive search, all the retrieved articles were sorted according to the number of citations. After that, they were manually refined and normalized to unify terms and to remove typographical, transcription or indexing errors. A detailed analysis was carried out to identify trends and reveal significant discriminators. For each article, the number of citations, year of publication, journal, first and senior author, journal name and country of origin of the authors and articles focusing on specific malignancy were studied.
Results: The number of citations for the top 100 chemotherapy articles ranged from 1675 to 8830 with a median of 2324 citations. Most of the articles (n=75) were published between 2000 -2010, 16 were published in the time frame of 25 years (1975-2000). More than half of the articles (n=54) were from the United States. New England Journal of Medicine made up almost half (n = 51) of the list. We found 5 authors who had up to 5 publications and rest contributed 3 or less than 3 articles.
Conclusion: This study revealed significant growth in chemotherapy literature in terms of the total number of journals, number of authors, organizations, and author collaborations.
Keywords: Bibliometrics, Chemotherapy, anticancer drugs,Impact factor, Web of Science (WOS),Scopus,Citations,Google Scholar
Introduction
Chemotherapy has evolved substantially over the past decades. Cancer is expected to increase by 50%, to almost 15 million cases by 2020, hence, it is assumed that the role of chemotherapy to battle cancer will continue to grow [1-3]. There is no previous bibliometric analysis on chemotherapy in the literature, although many other bibliometric studies have been published in various specialties and subspecialties [4,5]. To bridge this gap, we conducted a quantitative analysis of most referenced 100 chemotherapy articles to give oncologists a brief overview of landmark chemotherapy studies.
Bibliometric analysis is a quantitative assessment of the academic quality of authors, articles, text or journals by statistical methods and this analysis has been used to estimate the impact of a written article and track the correlation amongst citations of the academic journal [2,6]. Bibliometric studies have been of great interest in providing an overview and to evaluate research and scientific activity. They do so by calculating bibliometric indicators and information about the quantity of published research in a specific field.
The role of citation frequency has long been debated, yet it remains the most commonly used tool to identify important discoveries and studies which have had a disproportionate influence in a field [7]. Citation classics is an important parameter to prioritize research funding in this era, emphasizing costeffectiveness. With limited health care resources, bibliometric studies can help guide researchers and research funding agencies towards areas where restriction or an increase in research activity is warranted. Considering the importance of chemotherapy, research in this field has been increasing, and numerous articles are published annually, giving an insight into the development of new drugs to combat cancer at all stages (Figure 1). The present bibliometric analysis provides all the relevant data representative of 100 most-cited articles on chemotherapy (Table 1a). This study will enable researchers to acquire the latest information about the amount of work being done in this area and hence provide ideas on future challenges to focus on.
Methodology
We performed a database search on Scopus, Web of Science (WOS) and Google Scholar, and identified the top 100 most cited articles related to chemotherapy published in professional journals from 1910 to April 2019 by using search terms “Chemotherapy” and “Anti-Cancer Drugs”. The search yielded by two independent reviewers Iftikhar PM and Uddin MF showed a total number of 437,016 articles and the articles relevant to chemotherapy were shortlisted for inclusion (Table 1). These articles were ranked based on an absolute number of highest citations. Citation of Web of science was used for this analysis as WOS provides the coverage of articles from 1910 till present. The other two databases were checked for the counter reference of each article citation number and for other most-cited articles that were not available on Web of Science. No institutional or organizational review board approval was needed for our study as it was a retrospective evaluation of publicly available data. However, all the articles were published in the English language.
All the articles from various journals focusing on specialties of oncology, medicine, pathology, and pharmacology were included to ensure that none of the articles related to chemotherapy were overlooked. There were no restrictions on study types and abstract available. After an extensive search, all the retrieved articles were sorted according to the option “times cited”. We independently screened the abstracts to compile a list of the top 100 most cited chemotherapy articles. Each article is reviewed from the aspect of the number of citations, first author, year of publication, source journal, country of origin of the authors and institution [6].
The 100 articles were classified as basic science or clinical research studies and further categorized into sub-type studies like randomized controlled trials, cohort studies, cross-sectional studies, review articles, case series, case reports, and expert opinions. The h-index is defined as an index to qualify the effectiveness and citation impact of research publication of an individual [8]. H index was calculated to be 100 for this study. The relationship between the impact factor of a journal and the number of top 100 cited articles was analyzed using the Pearson product-moment correlation coefficient. All data is presented in the form of median and inter-quartiles (IQ). For all cases, a P-value of less than 0.05 was considered significant.
Results
The total number of citations of these 100 most-cited articles ranged from 1675 to 8830, with a median of 2324 citations and the most referenced five articles were cited more than 6000 times by authors of fraternity [6]. The 100 most-cited chemotherapy articles were published between 1975 and 2015 in 15 journals, with the most articles (n=75) published in 10 years extending from 2000 to 2010 (Table 2). In 2003 and 2004 most referenced articles (n=20) amongst the top 100 articles were published (Figure 1). Based on information about the first author we found that 100 most-cited articles originated from 13 different countries, with more than half from the USA (n=54), followed by the next most popular countries of UK (n=14) and France (n=10). Other countries of article origin included Canada, Italy, Germany, Australia, Belgium, Netherlands, Japan, and Switzerland (Figure 2).
Most referenced 100 articles were published in 15 journals and The New England Journal of Medicine (n=51), Journal of Clinical Oncology (n=16) and Lancet (n=10) contributed to most of the articles (Table 2). All other journals had less than 5 studies each. We found that De Bono J.S, had contributed seven articles and 3 authors (FehrenbacherL, Moore M.J, Van Custem E) had contributed four each among the top 100 articles. Other authors who contributed 3 papers each included Arriagada. R, Baselga. J, Bodrogi. I, Bryant. J, Cairncross. J.G, Cameron. D. The top 10 authors in our citation classic were De Bono J.S, Fehrenbacher. L, Moore M.J, VanCustem. E, Arriagada. R, Baselga. J, Bodrogi. I, Bryan. J, Cairncross, J.G, Cameron. D (Table 3).
Most articles were from US health care affiliations like Memorial Sloan Kettering Cancer Center (n=15), Dana-Farber Cancer Institute (n=14), University of Texas MD Anderson Cancer Center (n=12), while the others were from affiliations other than the USA like Princess Margaret Cancer Centre (n=12), Institute de Cancerologie Gustave Roussy (n=11) and the other affiliations of various countries contributed less than 10 publications (Figure 3).
Most of the research in chemotherapy was clinical research (n=74), while a few encompassed basic sciences and biochemical research (n=19) and others (n=7). Most of the articles were original articles (n=88), followed by review articles (n=11). The subtypes of these articles included prospective cohort, case reports, case series, cross-sectional studies, randomized controlled trials, animal studies, biochemical and in vitro studies. Among these 100 articles, a quarter of articles for chemotherapy were focused on lung cancer (n=23) followed by breast cancer (n=13) and colon cancer (n=12). The rest of the articles focused on other systems and were related to drug mechanics, drug resistance and treatment assessment. Within the list, we found a statistically significant correlation between the number of top-cited articles and the journal impact factor (P < 0.005) and the impact factor (IF) of journals ranged from 8.4 to 79.23. All the data have been tabulated to enhance understanding of the observations made in this study.
Discussion
Cancer is an international scourge and physicians across the world are discovering various neoplastic diseases in different parts of the world. At the same time in recent years, substantial effort has been made to search for better, more selective and effective drugs that could be used in the management of many different forms of neoplastic diseases at all stages. Chemotherapy, in combination with radiotherapy and surgery, is being incessantly studied and the clinical assessment of anticancer drugs by various controlled trials has been on the rise and has improved [9,10].
This citation classics allowed us to uncover historical patterns and trends in research which has impacted major change worldwide over the years [11,12]. Moreover, understanding the features inherent to frequently cited work would help young researchers to publish more effectively [13-15]. In recent years, many studies have provided insight into the citation frequency of the most-cited articles published in many journals and therefore, analyzing the frequency of article citations in chemotherapy, which has seen great advances and changed the world’s perspective towards cancer is necessary [16]. Citation analysis of articles plays a major role and is important in specific fields for both authors and journals. Journals use it to attract better articles, while it provides researchers with some related current information about diagnosis and therapy in their research areas, which should help them produce better work.
The number of articles labeled as “most-cited” or “top-cited” in various medical fields is increasing, but to date, there has been no bibliometric analysis of articles on chemotherapy. According to recent data, global cancer rates are estimated to increase by 50% to about 50 million cases by 2020 [1,15]. In our study 75 of the top 100, highly cited chemotherapy papers were published during 2000-2010. In contrast to bibliometrics published in orthopedics, neurosurgery and many other fields have reported their peak period for top-cited articles from 1965 to 1980 [17].
This suggests that the field of oncology is evolving rapidly and is in sync with chemotherapy as the patient treatment approach has become more scientific with the introduction of various studies and clinical trials on a wide basis all over the world. These clinical trials help in comparing new treatments to standard treatments and it plays a pivotal role in better understanding of risks and benefits of treatment [6,18]. Our findings of most cited published articles contraindicate the previously published hypothesis [12,16] that the article’s true value cannot be judged correctly until at least 3 decades after the publication. For our chemotherapy bibliometric, the peak period of 2000–2014 is not surprising considering that evolution in technology which has resulted in novel chemotherapies targeting cancer is relatively new [17,19].
When considering the timeline for bibliometrics, two important factors need to be considered. Firstly, according to obliteration by incorporation phenomenon which states that landmark articles are sometimes cited rarely because the information they provide becomes so widely used and embedded in the daily practice of each clinician, that researchers do not feel the need to cite that study [19]. Secondly, the inherent bias of bibliometrics against recent papers might lead to some extremely important papers not being included in such an analysis as it takes time to accumulate citations [14,20]. We further observed that the majority (n=76) of the top-cited chemotherapy articles were published in high impact factor journals such as The New England Journal of Medicine (n=51), Journal of Clinical Oncology (n=16) and Lancet (n=10).
It shows that researchers tend to publish important studies about oncology and chemotherapy in influential journals, the other journals contributed less than 5 articles each. It is interesting to note that most of the top-cited articles were published in general medicine journals, this can be explained by a concept proposed by Brookes called Bradford’s law, that most researchers get their citations from a few specific core journals and hence when authors decide to deviate from these journals, the impact of their article is reduced and thus most researchers try to stay loyal to those few famous journals [15,21]. Most researchers try to publish their articles in standard journals having higher impact factors despite variation in the field of interest. We found that the majority of the topcited chemotherapy articles focused on chemotherapy drugs targeting cancers like lung cancer (n=23), breast cancer (n=13), colon cancer (n=12) (Figure 4).
Such trends in major articles from our top 100 cited articles in the field of lung, breast. and colon cancer is not surprising as these malignancies are on the rise and are amongst the overall leading causes of mortality and morbidity. This provides vital information regarding major chemotherapy research in a field and it will help not only editors and stakeholders in selecting and judging future scientific work but also young scientists to do research effectively. Moreover, our study found that most articles (n=88) were original and a few (n=12) were review articles. It is important to consider that scientists who frequently produce high-quality work have a higher chance of academic promotion, and editors are more likely to accept their work and invite them to review articles [10].
Considering the burden of cancer is projected to rise, future bibliometric analyses may identify more papers on lung, breast, colon cancer and other topics such as innovations in the treatment of cancer through chemotherapies, strategies to provide remission of cancer in earlier stages, development of novel drugs which has no drug resistance potential. Despite all the advances in identifying appropriate drugs, a treatment which is selective in its attack on malignant cells exists, and only a limited percentage of patients with certain types of neoplastic disease benefit from chemotherapy. But on the other hand, the number of cancer patients to whom chemotherapy brings objective effect, including partial and complete remission of tumors, increases comparatively slowly.
This improvement is brought about by painstaking rigorous research into drug improvement, development of newer drugs with more efficacy, assessment of the treatment, development of drugs with fewer side effects, novel approaches to avoid drug resistance and methods of administration [9]. By international co-operation in the search for new drugs, and in their experimental screening and subsequent clinical trials, progress in the field could be sped up. To enhance cancer survivorship, we need collaboration among policymakers, researchers, and healthcare organizations for prevention, early detection and better prognosis [22].
Limitations
The Bibliometric analysis involves older published articles, while recently published high-quality studies would be ignored, a drawback which is related to the effect of the number of times cited. The value of contributions and progress in a field cannot be identified only by the number of citations. Therefore, having a lower citation frequency with good quality might have been missed. Lastly, the language of publication plays a major role, with a bias towards articles published in English language journals and from the developed world.
Conclusion
This bibliometric study provides a qualitative and quantitative evaluation of the most referenced chemotherapy articles in the literature. It also provides a detailed intuition into academic achievements, historical perspective that shaped the breadth of chemotherapy to serves as a guide for the scientific progress.
Authorship statement
Mohammad Faisal Uddin and Pulwasha Maria Iftikhar designed the study. All the authors performed the study, contributed to data extraction, literature review, analyzed the data, and wrote the paper.
Financial disclosure statement
This manuscript is original research, has not been previously published and has not been submitted for publication elsewhere while under consideration. Authors declare no conflict of interest with this manuscript. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
References
- RL Siegel, KD Miller, A Jemal (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1): 7-30.
- J Ferlay, I Soerjomataram, R Dikshit, S Eser, C Mathers, et al. (2012) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5): E359–E386.
- World Cancer Research Fund/American Institute for Cancer Research. Diet, Nutrition, Physical Activity and Cancer: A Global Perspective. Continuous Update Project Expert Report 2018.
- Guggenheim DE, Shah MA (2013) Gastric cancer epidemiology and risk factors. J Surg Oncol 107(3): 230–236.
- Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1): 9–29.
- Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, et al. (2010) AJCC Cancer Staging Manual. 7th (Edn), Springer, New York, USA.
- Washington K (2010) 7th edition of the AJCC cancer staging manual: stomach. Annals of Surgical Oncology 17(12): 3077–3079.
- Japanese Gastric Cancer Association (2011) Japanese gastric cancer treatment guidelines: 3rd English Edition. Gastric Cancer 14(2): 113–123.
- Kitano S, Iso Y, Moriyama M, Sugimachi K (1994) Laparoscopy assisted Billroth I gastrectomy. Laparosc Endosc 4(2): 146–148.
- Goh PM, Alponat A, Mak K, Kum CK (1997) Early international results of laparoscopic gastrectomies. Surg Endosc 11(6): 650–652.
- Zhang CD, Yamashita H, Zhang S, Seto Y (2018) Reevaluation of laparoscopic versus open distal gastrectomy for early gastric cancer in Asia: a meta-analysis of randomized controlled trials. Int J Surg 56: 31-43.
- J Ferlay, I Soerjomataram, R Dikshit, S Eser, C Mathers, et al. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5): E359–E386.
- L Zong, M Abe, Y Seto, J Ji (2016) The challenge of screening for early gastric cancer in China. Lancet 388(10060): 2606.
- Sumiyama K (2017) Past and current trends in endoscopic diagnosis for early stage gastric cancer in Japan, Gastric. Cancer 20(Suppl 1): 20–27.
- C Hamashima (2018) Cancer screening guidelines and policy making: 15 years of experience in cancer screening guideline development in Japan. J Clin Oncol 48(3): 278-286.
- Best LM, Mughal M, Gurusamy KS (2014) Laparoscopic versus open gastrectomy for gastric cancer. Cochrane Database of Systematic Reviews 3: CD011389.
- Azagra JS, Goergen M, De Simone P, Ibañez-Aguirre J (1999) Minimally invasive surgery for gastric cancer. Surg Endosc 13(4): 351-357.
- S Takiguchi, Y Fujiwara, M Yamasaki, H Miyata, K Nakajima, et al. (2013) Laparoscopy-assisted distal gastrectomy versus open distal gastrectomy. A prospective randomized single-blind study, World J Surg 37(10): 2379–2386.
- YW Kim, HM Yoon, YH Yun, BH Nam, BW Eom, et al. (2013) Long-term outcomes of laparoscopy-assisted distal gastrectomy for early gastric cancer: result of a randomized controlled trial (COACT 0301), Surg Endosc 27(11): 4267–4276.
- Cai J, Wei D, Gao CF, Zhang CS, Zhang H, et al. (2011) A prospective randomized study comparing open versus laparoscopy assisted D2 radical gastrectomy in advanced gastric cancer. Dig Surg 28(5-6): 331–337.
- JH Lee, HS Han, JH Lee (2005) A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric cancer: early results. Surg Endosc 19(2): 168-173.
- H Hayashi, T Ochiai, H Shimada, Y Gunji (2005) Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer. Surg Endosc 19(9): 1172-1176.
- S Kitano, N Shiraishi, K Fujii, K Yasuda, M Inomata, et al. (2002) A randomized controlled trial comparing open vs laparoscopy-assisted distal gastrectomy for the treatment of early gastric cancer: an interim report. Surgery 131(1 Suppl): S306–S311.
- Fujii K, Sonoda K, Izumi K, Shiraishi N, Adachi Y, et al. (2003) T lymphocyte subsets and Th1/Th2 balance after laparoscopy-assisted distal gastrectomy. Surg Endosc 17(9): 1440–1444.
- K Nakamura, H Katai, J Mizusawa, T Yoshikawa, M Ando, et al. (2013) A phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric Cancer (JCOG0912). Jpn J Clin Oncol 43(3): 324–327.
- K Misawa, M Fujiwara, M Ando, S Ito, Y Mochizuki, et al. (2015) Long-term quality of life after laparoscopic distal gastrectomy for early gastric cancer: results of a prospective multi-institutional comparative trial. Gastric Cancer 18(2): 417–425.
- JH Lee, BH Nam, KW Ryu, SY Ryu, YK Park, et al. (2015) Comparison of outcomes after laparoscopy-assisted and open total gastrectomy for early gastric cancer. Br J Surg 102(2015): 1500-1505.
- T Yoshikawa, H Cho, Y Rino, Y Yamamoto, M Kimura, et al. (2013) A prospective feasibility and safety study of laparoscopy-assisted distal gastrectomy for clinical stage I gastric cancer initiated by surgeons with much experience of open gastrectomy and laparoscopic surgery. Gastric Cancer 16(2): 126-132.
- H Katai, M Sasako, H Fukuda, K Nakamura, N Hiki (2010) JCOG Gastric Cancer Surgical Study
Group, Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG 0703). Gastric Cancer 13: 238–244.
- Y Kurokawa, H Katai, H Fukuda, M Sasako (2008) Gastric Cancer Surgical Study Group of the Japan Clinical Oncology Group, Phase II study of laparoscopy-assisted distal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group Study JCOG0703. Jpn J Clin Oncol 38(7): 501–503.
- JY An, GU Heo, JH Cheong, WJ Hyung, SH Choi, et al. (2010) Assessment of open versus laparoscopy-assisted gastrectomy in lymph node-positive early gastric cancer: a retrospective cohort analysis. J Surg Oncol 102(1): 77-81.
- Y Wang, S Wang, ZQ Huang, WP Chou (2014) Meta-analysis of laparoscopy assisted distal gastrectomy and conventional open distal gastrectomy for EGC. Surgeon 12(1): 53–58.
- Y Deng, Y Zhang, TK Guo TK (2015) Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: A meta-analysis based on seven randomized controlled trials. Surg Oncol 24(2): 71–77.
- W Lu, J Gao, J Yang, Y Zhang, W Lv, et al. (2016) Long-term clinical outcomes of laparoscopy-assisted distal gastrectomy versus open distal gastrectomy for early gastric cancer: A comprehensive systematic review and meta-analysis of randomized control trials. Medicine (Baltimore) 95(27): e3986.
- JPT Higgins, S Green (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration.
- Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
- Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0.). Hoboken: John Wiley & Sons Inc, New Jersey, USA.
- Inaba T, Okinaga K, Fukushima R, Iinuma H, Ogihara T, et al. (2004) Prospective randomized study of two laparotomy incisions for gastrectomy: midline incision versus transverse incision. Gastric Cancer 7(3): 167–171.
- Stuart RC (1997) 4 - Radical gastrectomy - how do I do it?. European Journal of Cancer 33(Suppl 8): S5.
- Lee HJ, Yang HK (2013) Laparoscopic gastrectomy for gastric cancer. Digestive Surgery 30(2): 132-141.
- Han SU (2014) Laparoscopy-assisted endoscopic full-thickness resection with basin lymphadenectomy based on sentinel lymph nodes for early gastric cancer. J Am Coll Surg 219(3): e29–37.
- Kawamura H, Homma S, Yokota R, Yokota K, Watarai H, et al. (2008) Inspection of safety and accuracy of D2 lymph node dissection in laparoscopy-assisted distal gastrectomy. World J Surg 32(11): 2366–2370.
- Lee SJ, Hyung WJ, Koo BN, Lee JY, Jun NH, et al. (2008) Laparoscopy-assisted subtotal gastrectomy under thoracic epidural-general anesthesia leading to the effects on postoperative micturition. Surgical Endoscopy 22(3): 724–730.
- Lee JH, Yom CK, Han HS (2009) Comparison of longterm outcomes of laparoscopy-assisted and open distal gastrectomy for early gastric cancer. Surgical Endoscopy 23(8): 1759-1763.
- Li HT, Han XP, Su L, Zhu WK, Xu W, et al. (2014) Short-term efficacy of laparoscopy-assisted vs open radical gastrectomy in gastric cancer. World J Gastrointest Surg 6(4): 59–64.
- Lin W, Li Z, Xu Y, Xie X, Huang Z, et al. (2014) Comparative study of laparoscopic gastrectomy D2 radical surgery and open gastrectomy for upper stomach cancer. Cancer Research and Clinic 26(5): 332–335.
- DU XH, Li R, Chen L, Shen D, Li SY, et al. (2009) Laparoscopyassisted D2 radical distal gastrectomy for advanced gastric cancer: initial experience. Chin Med J (Engl) 122(12): 1404-1407.
- Jiang L, Yang KH, Guan QL, Cao N, Chen Y, et al. (2013) Laparoscopy-assisted gastrectomy versus open gastrectomy for resectable gastric cancer: an update meta-analysis based on randomized controlled trials. Surg Endosc 27(7): 2466–24
- Cheng QY, Pang TCY, Hollands MJ, Richardson AJ, Pleass H, et al. (2014) Systematic review and meta-analysis of laparoscopic versus open distal gastrectomy. J Gastrointest Surg 18: 1087-10
- Aurello P, Sagnotta A, Terrenato I, Berardi G, Nigri G, et al. (2016) Oncologic value of laparoscopy-assisted distal gastrectomy for advanced gastric cancer: a systematic review and meta-analysis. J Minim Access Surg 12(3): 199–
- Inokuchi M, Otsuki S, Ogawa N, Tanioka T, Okuno K, et al. (2016) Postoperative complications of laparoscopic total gastrectomy versus open total gastrectomy for gastric cancer in a meta-analysis of high-quality case-controlled studies. Gastroenterol Res Pract 27(5): 1509-1520.
- XZ Chen, JK Hu, K Yang, L Wang, QC Lu (2009) Short-term evaluation of laparoscopy-assisted distal gastrectomy for predictive early gastric cancer: a meta-analysis of randomized controlled trials. Surg Laparosc Endosc Percutan Tech 19(4): 277–284.
- H Ohtani, Y Tamamori, K Noguchi, T Azuma, S Fujimoto, et al. (2010) A meta-analysis of randomized controlled trials that compared laparoscopy-assisted and open distal gastrectomy for early gastric cancer. J Gastrointest Surg 14: 958–964.
- Y Liang, G Li, P Chen, J Yu, C Zhang (2011) Laparoscopic versus open gastrectomy for early distal gastric cancer: a meta-analysis. ANZ J Surg 81(10): 673–680.
- YK Zeng, ZL Yang, JS Peng, HS Lin, L Cai (2012) Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: evidence from randomized and nonrandomized clinical trials. Ann Surg 256(1): 39–52.
- Scatizzi M, Kröning KC, Lenzi E, Moraldi L, Cantafio S, et al. (2011) Laparoscopic versus open distal gastrectomy for locally advanced gastric cancer: a case-control study. Updates Surg 63(1): 17-23.
- Shinohara T, Satoh S, Kanaya S, Ishida Y, Taniguchi K, et al. (2013) Laparoscopic versus open D2 gastrectomy for advanced gastric cancer: a retrospective cohort study. Surg Endosc 27(1): 286-294.
- Lee J, Kim YM, Woo Y, Obama K, Noh SH, et al. (2015) Robotic distal subtotal gastrectomy with D2 lymphadenectomy for gastric cancer patients with high body mass index: comparison with conventional laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy. Surg Endosc 29(11): 3251–3260.
- Kim HI, Han SU, Yang HK, Kim YW, Lee HJ, et al. (2016) Multicenter prospective comparative study of robotic versus laparoscopic Gastrectomy for gastric Adenocarcinoma. Ann Surg 263(1): 103–109.
- Okumura N, Son T, Kim YM, Kim HI, An JY, et al. (2016) Robotic gastrectomy for elderly gastric cancer patients: comparisons with robotic gastrectomy in younger patients and laparoscopic gastrectomy in the elderly. Gastric Cancer 19(4): 1125–1134.
- Luo GD, Cao YK, Gong JQ, Wang XH, Wang B, et al. (2017) Hand-assisted laparoscopic versus open surgery radical gastrectomy for advanced distal gastric cancer: a prospective randomized study. Int J Clin Exp Med 10: 5001–50
- Inaki N, Etoh T, Ohyama T, Uchiyama K, Katada N, et al. (2015) A multi-institutional, prospective, phase II feasibility study of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for locally advanced gastric cancer (JLSSG0901). World J Surg 39(11): 2734–27
- Kim HI, Hur H, Kim YN, Lee HJ, Kim MC, et al. (2014) Standardization of D2 lymphadenectomy and surgical quality control (KLASS-02-QC): a prospective, observational, multicenter study [NCT01283893]. BMC Cancer 14: 209.
- S Sakuramoto, K Yamashita, S Kikuchi, N Futawatari, N Katada, et al., Laparoscopy versus open distal gastrectomy by expert surgeons for early gastric cancer in Japanese patients: short-term clinical outcomes of a randomized clinical trial. Surg Endosc 27(5): 1695–1705.
- YW Kim, YH Baik, YH Yun, BH Nam, DH Kim et al. (2008) Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. Ann Surg 248(5): 721–727.
- HH Kim, WJ Hyung, GS Cho, MC Kim, SU Han et al. (2010) Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report-a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg 251(3): 417–420.
- Kim YW, Park YK, Yoon HM, Nam BH, Ryu KW, et al. (2013) Result of clinical study on feasibility of laparoscopy assisted D2 distal gastrectomy to treat advanced gastric cancer (COACT_1001). J Clin Oncol 31(15): 4105.
- Nam BH, Kim YW, Reim D, Eom BW, Yu WS, et al. (2013) Laparoscopy assisted versus open distal gastrectomy with D2 lymph node dissection for advanced gastric cancer: design and rationale of a phase II randomized controlled multicenter trial (COACT 1001). J Gastric Cancer 13(3): 164–1
- Hu YF, Huang CM, Sun YH, Su XQ, Li ZY, et al. (2015) Laparoscopic D2 distal gastrectomy versus conventional open surgery for advanced gastric cancer: the safety analysis from a multicenter prospective randomized controlled trial in China (CLASS-01 Trial). J Clin Oncol 33(3): 1350-1357.
- Wang Z, Xing J, Cai J, Zhang Z, Li F, et al. (2018) Short-term surgical outcomes of laparoscopy-assisted versus open D2 distal gastrectomy for locally advanced gastric cancer in North China: a multicenter randomized controlled trial. Surg Endosc 33(1): 33–
- Shi Y, Xu X, Zhao Y, Qian F, Tang B, et al. (2018) Short-term surgical outcomes of a randomized controlled trial comparing laparoscopic versus open gastrectomy with D2 lymph node dissection for advanced gastric cancer. Surg Endosc 32(5): 2427-24
- Park YK, Yoon HM, Kim YW, Park JY, Ryu KW, et al. (2018) Laparoscopy-assisted versus open D2 distal gastrectomy for advanced gastric cancer: results from a randomized phase II multicenter clinical trial (COACT 1001). Ann Surg 267(4): 638-6
- H Katai, J Mizusawa, H Katayama, M Takagi, T Yoshikawa, et al. (2017) Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastriccancer: Japan Clinical Oncology Group Study JCOG0912. Gastric Cancer 20(4): 699-708.
- K Yamashita, S Sakuramoto, S Kikuchi, N Futawatari, N Katada, et al. (2016) Laparoscopic versus open distal gastrectomy for early gastric cancer in Japan: long-term clinical outcomes of a randomized clinical trial Surg Today 46(6): 741-749.
- W Kim, HH Kim, SU Han, MC Kim, WJ Hyung (2016) Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group, Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared with Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes from a Multicenter Randomized Controlled Trial (KLASS-01). Ann Surg 263: 28-35.
- Hu Y, Huang C, Sun Y, Su X, Cao H, et al. (2016) Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial. J Clin Oncol 34(12): 1350-135
- Cui M, Li Z, Xing J, Yao Z, Liu M, et al. (2015) A prospective randomized clinical trial comparing D2 dissection in laparoscopic and open gastrectomy for gastric cancer. Med Oncol 32(10): 241.
- Aoyama T, Yoshikawa T, Hayashi T, Hasegawa S, Tsuchida K, et al. (2014) Randomized comparison of surgical stress and the nutritional status between laparoscopy assisted and open distal gastrectomy for gastric cancer. Ann Surg Oncol 21(6): 1983-1990.
- Chen Hu J, Xin Jiang L, Cai L, Tao Zheng H, et al. (2012) Preliminary experience of fast-track surgery combined with laparoscopy-assisted radical distal gastrectomy for gastric cancer. J Gastrointest Surg 16(10): 1830-1839.
- Huscher CG, Mingoli A, Sgarzini G, Sansonetti A, Di Paola M, et al. (2005) Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: Five-year results of a randomized prospective trial. Ann Surg 241(2): 232-237.
- Strong VE, Song KY, Park CH, Jacks LM, Gonen M, et al. (2010) Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg 251(4): 640–646.
- Hyung WJ, Song C, Cheong JH, Choi SH, Noh SH (2007) Factors influencing operation time of laparoscopy-assisted subtotal gastrectomy: analysis of consecutive initial 100 cases. Eur J Surg Oncol 33(3): 314-319.
- Seto Y, Nagawa H, Muto T (1997) Impact of lymph node metastasis on survival with early gastric cancer. World J Surg 21(2): 186-189.
- Siewert JR, Bottcher K, Stein HJ, Roder JD (1998) Relevant prognostic factors in gastric cancer: ten-year results of the German gastric cancer study. Ann Surg 228(4): 449–461.
- Roviello F, Rossi S, Marrelli D, Pedrazzani C, Corso G, et al. (2006) Number of lymph node metastases and its prognostic significance in early gastric cancer: a multicenter Italian study. J Surg Oncol 94(4): 275-280.